Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy.

@article{Packer1990CalciumCB,
  title={Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy.},
  author={Milton Packer},
  journal={Circulation},
  year={1990},
  volume={82 6},
  pages={
          2254-7
        }
}
  • M. Packer
  • Published 1 December 1990
  • Medicine
  • Circulation
oncerns have been raised about safety of calcium channel blockers in patients with heart failure since their introduction into cardiovascular medicine more than 25 years ago. By inhibiting the influx of calcium into myocardial cells, calcium channel-blocking drugs can depress contractility in both experimental systems and the clinical setting. The magnitude of this effect is enhanced when these drugs are combined with other negative inotropic agents (e.g., ,8-blockers) or when they are… Expand
View on PubMed
ahajournals.org
117 Citations
Background Citations
8

117 Citations

Citation Type

Citation Type

Evolving Role of Calcium Channel Blockers in Heart Failure
TLDR
Amlodipine increases exercise time and reduces symptoms and plasma norepinephrine concentration in heart failure, and appears to be effective as primary therapy for patients with dilated cardiomyopathy. Expand
Calcium Antagonist Use in Congestive Heart Failure: Still a Bridge Too Far?
  • R. Piepho
  • Medicine
  • Journal of clinical pharmacology
  • 1995
TLDR
Until conclusive clinical evidence of the safety and effectiveness of calcium antagonists in the treatment CHF is available, they should not be used to treat this disease unless individual patient characteristics clearly indicate a positive benefit/risk ratio. Expand
Calcium antagonists in patients with left ventricular dysfunction: back on the bridge?
  • B. Lewis
  • Medicine
  • Journal of cardiac failure
  • 1996
TLDR
Use of these drugs minimizes the peak and trough effect associated with short-acting preparations, and particularly when administered against a background of digoxin, diuretic and angiotensin converting enzyme inhibitors, may be associated with better long-term results in patients with ventricular dysfunction. Expand
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: Focus on felodipine
TLDR
Preliminary studies in patients with heart failure indicate that felodipine and amlopidine may improve hemodynamics, reduce neurohormonal activation, and increase exercise tolerance, but final conclusions must await the randomized clinical trials now underway. Expand
Use of Calcium Antagonists After Myocardial Infarction: Focus on the DEFIANT Studies
TLDR
Second and third-generation vasoselective drugs with enhanced safety profile and a longer duration of action were developed to minimize the myocardial depressant effect which characterized the first-generation calcium antagonists. Expand
Safety of calcium antagonists in patients with congestive heart failure.
  • S. Katz
  • Medicine
  • Clinical therapeutics
  • 1997
TLDR
Although the preliminary experience with long-acting dihydropyridine CAs in heart failure has been encouraging, safety concerns raised by past trials dictate that no CA can be recommended for the treatment of heart failure at this time. Expand
Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
TLDR
The data do not support the use of dihydropyridines when primarily given as treatment for CHF, but the results suggest that these drugs can be safely given to patients with left ventricular dysfunction or CHF who need additional treatment for angina pectoris or hypertension. Expand
The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).
TLDR
A 2,400-patient international trial assessing the ability of mibefradil to impact upon survival and symptoms of heart failure in patients who are in NYHA classes II–IV and who were already treated with standard therapy. Expand
A Neurohormonal Modulator in Heart Failure?
Clinical Use of Digitalis Glycosides The potential benefit of digoxin therapy in heart failure patients is thought to be related to its positive inotropic effect that increases cardiac output and… Expand
Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity
  • L. Opie
  • Medicine
  • Cardiovascular Drugs and Therapy
  • 2004
TLDR
It is proposed that cytosolic calicum overload could play a role in ischemic ventricular fibrillation and that verapamil prevented postinfarct sudden death, which implies a potential antiarrhythmic mechanism. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far.
TLDR
Although some patients with severe chronic heart failure have been reported to benefit from short-term calcium-channel blockade, the hemodynamic benefits seen are modest compared with those from conventional vasodilator drugs, and little long-term improvement has been observed in randomized, double-blind trials. Expand
Efficacy of felodipine in congestive heart failure.
TLDR
Felodipine has a beneficial effect in patients with moderately severe heart failure and further research is necessary to demonstrate its long-term efficacy and safety. Expand
Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.
TLDR
Nisoldipine, a calcium entry blocker, was given to 10 patients with congestive heart failure and caused some beneficial chronic hemodynamic effects, but its chronic renal and neurohumoral effects were not as favorable. Expand
Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.
TLDR
Felodipine significantly increased resting and exercise cardiac output without producing concomitant changes in resting or exercise heart rate or right and left ventricular filling pressures and resulted in significant fluid retention. Expand
Cardiovascular and neurohumoral postural responses and baroreceptor abnormalities during a course of adjunctive vasodilator therapy with felodipine for congestive heart failure.
TLDR
Felodipine normalizes baroreflex control of vascular resistance in patients with CHF, and Regulation of FSVR during the sympathetic stimulation of orthostatic stress was further elucidated. Expand
Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure.
The acute hemodynamic effects of 20 to 50 mg of orally administered nifedipine were evaluated in 31 patients with severe chronic congestive heart failure (CHF) and the results were analyzed according… Expand
Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial.
TLDR
It is demonstrated that improvement of left ventricular function alone cannot be reliably interpreted as proof of clinical efficacy of therapeutic interventions in patients with heart failure and long-term minoxidil administration was associated with a poorer clinical course. Expand
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
TLDR
Data suggest that neuroh hormonal systems may exert a deleterious effect on the survival of some patients with severe chronic heart failure, which may be favorably modified by long-term treatment with specific neurohormonal antagonists. Expand
Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy.
TLDR
The results suggest that nifedipine and captopril have different effects on afterload and contractility and these may account for the different effects of these drugs on the performance of the heart and clinical responses. Expand
Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction.
TLDR
To determine the clinical significance of the occurrence of hemodynamic deterioration after the administration of calcium channel blocking drugs, nifedipine was administered to 29 patients with severe left ventricular dysfunction and 13 patients showed hemodynamic improvement with the drug, as shown by a notable increase in cardiac index and a modest decrease in mean arterial pressure. Expand
...
1
2
3
4
...